TaME-seq (tagmentation-assisted multiplex PCR enrichment sequencing) is a tool for detection of viral variation and integration.
Human papillomavirus (HPV) is the main cause of cervical cancer, which is one of the most common cancers in women worldwide. The tool can indicate if the patient has a transient or persistent HPV infection where the latter is associated with a higher cancer risk and may be implemented to validate the effect of HPV vaccines or function as a research tool.
The protocol is also adapted to SARS-Cov-2 and can be used as a vaccine surveillance tool.
- Variant detection (inter and intra host) – SARS-Cov-2 and HPV
- Viral integration – HPV
- Viral infection – SARS-Cov-2
- Identify chain of infection – SARS-Cov-2 and HPV
- Vaccine surveillance – SARS-Cov-2and HPV
- Research tool – SARS-Cov-2 and HPV
- Cancer screening – HPV
TaME-seq provides higher analyses depth than any other HPV test on the market and can detect both HPV variation and chromosomal integration. The tool may be implemented to validate the effect of HPV vaccines or function as a research tool. The protocol is also adapted to SARS-Cov-2 and could be applied as a surveillance tool. TaME-seq is applicable to large sample cohorts leading to reduced sequencing costs.
- Efficient viral target enrichment
- Simultaneous analysis of variation and integration
- Inexpensive and robust one-day sample preparation
- Low input – 20 ng of total DNA
- Other DNA and RNA viruses can be designed
Lagström et al, 2019 Sci Rep and J Clin Virol
National patent application is filed in US May 2021 (WO/2016/090266) and covers the primer sites and the specialized bioinformatic pipeline and claim diagnostic, prognostic and predictive use of the technology.
Inven2 AS seeks partners for co-development and/or licensing of the technology.